tert-butyl N-[3-(methanesulfonyloxy)-2-methylpropyl]carbamate | 480452-01-5

• 英文名称: tert-butyl N-[3-(methanesulfonyloxy)-2-methylpropyl]carbamate
• 英文别名: 1,1-Dimethylethyl N-[2-methyl-3-[(methylsulfonyl)oxy]propyl]carbamate；[2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] methanesulfonate
• CAS: 480452-01-5
• 化学式: C₁₀H₂₁NO₅S
• 分子量: 267.346
• InChiKey: NBQQGCSKRZEWAE-UHFFFAOYSA-N

物化性质

• 沸点：
  418.0±28.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[3-(methanesulfonyloxy)-2-methylpropyl]carbamate 在 potassium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-{2-methyl-3-[4-(2-{4-[(2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}pyrimidin-4-yl)methoxy]phenyl}propan-2-yl)phenoxy]propyl}carbamate
  参考文献：
  名称：

  一种双功能嵌合体杂环化合物及其作为雄激素受体降解剂的用途

  摘要：

  本发明提供了式Ⅰ所示化合物、或其光学异构体、或其溶剂合物、或其药学上可接受的盐、或其前体药物、或其互变异构体、或其内消旋体、或其外消旋体、或其对映异构体、或其非对映异构体、或其混合物形式、或其代谢产物、或其代谢前体、或其同位素替代形式。其中TB为靶点识别/结合部分，L为链接部分，U为泛素蛋白酶识别/结合部分；三个部分通过化学键相连接。本发明化合物能够显著下调全长及变异的雄激素受体(AR)蛋白，对前列腺癌细胞系有良好的抑制活性。本发明式I所示的化合物可用于制备靶向调控雄激素受体的蛋白降解靶向嵌合体和治疗受雄激素受体调控的相关疾病药物，特别是在治疗前列腺癌、乳腺癌的药物中具有很好的应用前景。

  公开号：

  CN115677667A

文献信息

• (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
  申请人：Schering AG

  公开号：US20030194371A1

  公开（公告）日：2003-10-16

  The invention relates to (ethylene)-(propylene)-triaminepentaacetic acid derivatives that are substituted on both the ethylene bridge and the propylene bridge, as well as conjugates of these compounds with biomolecules. The compounds and conjugates are suitable as agents for NMR diagnosis and radiodiagnosis as well as for radiotherapy.

  该发明涉及在乙烯桥和丙烯桥上取代的(乙烯)-(丙烯)-三胺五乙酸衍生物，以及这些化合物与生物分子的结合物。这些化合物和结合物适用于核磁共振诊断和放射诊断代理，以及放射治疗。
• (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
  申请人：——

  公开号：US20040258620A1

  公开（公告）日：2004-12-23

  The invention relates to a novel class of ligands, complexes comprising such ligands and a metal ion, and adducts of these metal complexes and a macromolecule. Pharmaceutical compositions and methods of making and using the ligand-metal complexes are also described. The invention also relates to the use of macromolecular adducts for enhancement of diagnostic imaging. In particular, the invention relates to (ethylene)-(propylene)-triaminepentaacetic acid (EPTPA) derivatives, a process for their production, and their use for the production of pharmaceutical agents for NMR diagnosis or radiodiagnosis or radiotherapy.

  本发明涉及一类新型配体、由此类配体和金属离子组成的络合物，以及这些金属络合物和大分子的加合物。本发明还描述了配体-金属络合物的药物组合物及制造和使用方法。本发明还涉及使用大分子加合物增强诊断成像。特别是，本发明涉及(乙烯)-(丙烯)-三胺五乙酸(EPTPA)衍生物、其生产工艺及其用于生产核磁共振诊断或放射诊断或放射治疗的药剂。
• (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS
  申请人：Schering Aktiengesellschaft

  公开号：EP1397339A1

  公开（公告）日：2004-03-17
• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20150353538A1

  公开（公告）日：2015-12-10

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
• INHIBITORS OF LEUCINE RICH REPEAT KINASE 2
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20200392158A1

  公开（公告）日：2020-12-17

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).